Every ADC in development right now follows the same rulebook.
Find an antigen that’s high on cancer cells and low on normal cells. Make an antibody against it. Attach a cytotoxic payload. Hope the differential is big enough that you kill the tumor before you kill the patient.
It works when you have a good antigen. HER2. TROP2. CD79b. Dozens of approved or late-stage ADCs now use this template.
It falls apart when you don’t have one. Or when the tumor stops expressing it. Or when the “good” antigen turns out to also exist on some critical normal tissue nobody checked carefully.
OncoNano Medicine is building a different kind of ADC. One that doesn’t need an antigen at all.
Yesterday at AACR 2026, they presented preclinical data for ONM-421, the first asset built on their ON-BOARD platform. Instead of using an antibody to find the tumor, ONM-421 uses pH.
How ON-BOARD works
Antigen-independent tumor targeting via acidic microenvironment.
Tumors are acidic. Not a little acidic. Measurably acidic compared to normal tissue, because cancer cells metabolize glucose differently and dump lactic acid everywhere. This has been known since Otto Warburg figured it out in 1924.
OncoNano built a polymer that recognizes that pH drop. Circulating in blood at pH 7.4, the polymer stays intact and holds onto its payload. Drops into a tumor at pH 6.5, the polymer falls apart and dumps MMAE. That’s the same cytotoxic payload used in Adcetris and Padcev and a dozen other approved ADCs.
Chemistry doing the targeting. No antibody, no antigen, no receptor. The drug reacts to a property that basically every solid tumor has.
The preclinical data shows tumor-selective MMAE delivery and tumor growth inhibition in multiple models. In vitro and in vivo activity across different payload types. Activity described as improved versus standard treatments, though OncoNano didn’t disclose specific numbers.
This isn’t OncoNano’s first rodeo. Their ONM-501 asset, a pH-sensitive STING agonist, is already in Phase 1 for advanced solid tumors. And they’ve taken two imaging agents through Phase 2 trials, with pegsitacianine for intraoperative tumor detection being the most advanced.
The platform is the story here. Most companies developing novel ADC targeting approaches are still operating within the antigen framework. Find a better antigen. Engineer a better antibody. Tune a better linker.
OncoNano is asking a different question. What if you don’t need any of that?
If pH-sensitive delivery works in human tumors, and that’s the question ONM-421 will eventually answer in the clinic, it opens up a lot of ground that ADCs can’t reach.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you. Contextualized and written directly to you. So you cut through the noise and immediately understand why it matters.
